Medical management of Crohn's disease: A guide for radiologists

European Journal of Radiology

Volumn 69, Issue 3, 2009, Pages 371-374

  Helper, Debra J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Crohn's disease; Medical treatment

Indexed keywords

CROHN'S DISEASE; MEDICAL MANAGEMENTS; MEDICAL TREATMENT;

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; MESALAZINE; NATALIZUMAB; PLACEBO; PREDNISONE;

ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; HUMAN; INTESTINE FISTULA; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DIAGNOSTIC IMAGING; DIGESTIVE SYSTEM SURGICAL PROCEDURES; GASTROINTESTINAL AGENTS; HUMANS;

EID: 62849096209     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2008.11.028     Document Type: Article

References (49)

1. Gasche C., Scholmerich J., Brynskov J., et al. A simple classification of Crohn's disease: report of the working party of the World Congresses of Gastroenterology Vienna 1998. Inflamm Bowel Dis 6 (2000) 8-15
2. Satsangi J., Silverberg M.S., Vermiere S., et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55 (2006) 749-753
3. Louis E., Collard A., Oger A.F., et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 49 (2001) 777-782
4. Cosnes J., Cattan S., Blain A., et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 8 4 (2002) 244-250
5. Henriksen M., Jahnsen J., Lygren I., et al. Clinical course of Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol 42 (2007) 602-610
6. Vernier-Massouille G., Balde M., Salleron J., et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 135 (2008) 1106-1113
7. Van Limbergen J., Russell R.K., Drummond H.E., et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 135 (2008) 1114-1122
8. Hanauer S.B., and Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2 (2004) 379
9. Summers R.W., et al. National cooperative Crohn's disease: results of drug treatment. Gastroenterology 77 (1979) 847
10. Van Hees P.A., Van Lier H.J., Van Eleteren P.H., et al. Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study. Gut 22 (1981) 404
11. Benchimol E., Seow Ch, Steinhart A., and Griffiths A. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2 (2008) CD006792
12. Greenberg G., Feagan B.G., Martin F., et al. Oral budesonide for active Crohn's disease. N Engl J Med 331 (1994) 836-841
13. Thomsen O., Cortot A., Jewell D., et al. A comparison of budesonide and mesalamine for active Crohn's disease. N Engl J Med 339 (1998) 370-374
14. Rutgeerts P., Lofberg R., Malchow H., et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 331 (1994) 842-845
15. Targan S.R., Hanauer S.B., vanDeventer S., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 337 (1997) 1029-1035
16. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC I trial. Gastroenterology 130 (2006) 323-333
17. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol for management of Crohn's disease. N Engl J Med 357 (2007) 228-238
18. Mackey A.C., Green L., Liang L.C., et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44 (2007) 265-267
19. Vermeire S., Norman M., Van Assche G., et al. Effectiveness of concomitant immunosuppressive therapy to suppress formation of antibodies to infliximab in Crohn's disease. Gut 56 (2007) 1226-1231
20. Parsi M.A., Achkar J.P., Richardson S., et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 123 (2002) 707-713
21. Targan S.R., Feagan B.G., Fedorak R.N., et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132 (2007) 1672-1683
22. Van Assche G., Van Ranst M., Sciot R., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353 (2005) 362-368
23. Messori A., Brignola C., Trallori G., et al. Effectiveness of 5-aminoalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 89 (1994) 692
24. Sandborn W.J., Lofberg R., Feagan B.G., et al. Budesonide for maintenance of remission in patients with Crohn's disease in a medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 100 (2005) 1780-1787
25. Ewe K., Press A.G., Singe C.C., et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 105 (1993) 367
26. Pearson D.C., May G.R., Fick G., and Sutherland L.R. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev (2000) CD000067
27. Markowitz J., Grancher K., Kohn N., et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119 (2000) 895-902
28. Kandiel A., Fraser A.G., Korelitz B.I., et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54 (2005) 1121-1125
29. Feagan B.G., Rochon J., Fedorak R., et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 332 (1995) 292-297
30. Feagan B.G., Fedorak R.N., Irvine E.J., et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med 342 (2000) 1627-1632
31. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 359 (2002) 1541-1549
32. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM study. Gastroenterology 132 (2007) 52-65
33. Sandborn W.J., Hanauer S.B., Rutgeerts P., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56 (2007) 1232-1239
34. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357 (2007) 239-250
35. Sandborn W.J., Colombel J.F., Enns R., et al. Natalizumab induction and maintenance therapy for Crohn's disease. NEJM 353 (2005) 1912-1925
36. Sandborn W.J., Rutgeerts P., Enns R., et al. Adalimumab induction therapy in Crohn disease previously treated with infliximab. Ann Int Med 146 (2007) 829-838
37. Present D.H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
38. Present D.H., Korelitz B.I., Wisch N., et al. Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 302 (1980) 981
39. Present D.H., and Lichtiger S. Efficacy of cyclosporine in treatment of fistula in Crohn's disease. Dig Dis Sci 39 (1994) 374
40. Sandborn W.J., Present D.H., Isaacs K.L., et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 125 (2003) 380
41. Sands B.E., Blank M.A., Patel K., and van Deventer S.J. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2 (2004) 912
42. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004) 876-885
43. Cottone M., Rosselli M., and Orlando A. Smoking habit and recurrence in Crohn's disease. Gastroenterology 106 (1994) 643-648
44. Kim N.K., Senagore A.J., Luchtefeld M.A., et al. Long-term outcome after ileocecal resection for Crohn's disease. Am Surg 63 (1997) 627
45. Rutgeerts P., Peeters M., Hiele M., et al. A placebo controlled trial of metronidazole for recurrence prevention of Crohn's disease after resection of the terminal ileum. Gastroenterology 108 (1995) 1617-1621
46. D'Haens G., Vermeire S., van Assche G., et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 135 (2008) 1123-1129
47. Ardizzone S., Maconi G., Sampietro G., et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 127 (2004) 730-740
48. Hanauer S.B., Korelitz B., Rutgeerts P., et al. Postoperative maintenance of Crohn's disease remission with 6MP, mesalamine or placebo: a 2-year trial. Gastroenterology 127 (2004) 723-729
49. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomized trial. www.thelancet.com 2008;371:660-7.